Corcept Therapeutics Inc.
CORTCorcept Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of severe and rare metabolic and psychiatric disorders. It is best known for its portfolio of cortisol receptor modulators, including mifepristone, which is approved for the treatment of Cushing's syndrome and psychotic mood disorders. The company's pipeline also includes other compounds targeting conditions related to cortisol dysregulation.
Company News
Corcept Therapeutics' Chief Development Officer William Guyer sold 20,000 shares worth $1.9 million on July 7, 2026, under a pre-scheduled Rule 10b5-1 trading plan established in November 2024. Despite liquidating 83% of his direct holdings, Guyer retains 130,000 stock options. The sale comes as Corcept achieved FDA approval for Lifyorli (cortiso...
The article compares two healthcare-focused ETFs: State Street SPDR S&P Pharmaceuticals (XPH) and First Trust NYSE Arca Biotechnology Index Fund (FBT). XPH offers lower costs (0.35% expense ratio vs 0.55%), broader diversification with 59 holdings, and better 1-year performance (38% vs 35.90%), plus dividend income. FBT provides more concentrated...
Pomerantz Law Firm has filed class action lawsuits against Corcept Therapeutics, Eos Energy Enterprises, and Nektar Therapeutics. The primary case involves Corcept, which faced a 50.4% stock price decline after the FDA issued a Complete Response Letter for its relacorilant drug, citing insufficient evidence of effectiveness. Investors with losses...
A class action lawsuit has been filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) alleging that company executives made materially false and misleading statements about the clinical trial strength and regulatory prospects of their drug relacorilant. The complaint claims defendants overstated the drug's approval chances while conceali...
A class action lawsuit has been filed against Corcept Therapeutics for allegedly misleading investors about its relacorilant drug candidate for Cushing's syndrome. The company claimed the clinical trials provided 'powerful support' for FDA approval, but the FDA issued a Complete Response Letter citing insufficient evidence of effectiveness. Corce...
